Istituto di Ricerche Farmacologiche Mario Negri, IRCCS, Milan, Italy.
Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Eur J Neurol. 2021 Oct;28(10):3303-3323. doi: 10.1111/ene.14652. Epub 2021 Jan 3.
The COVID-19 pandemic is a global public health issue. Neurological complications have been reported in up to one-third of affected cases, but their distribution varies significantly in terms of prevalence, incidence and phenotypical characteristics. Variability can be mostly explained by the differing sources of cases (hospital vs. community-based), the accuracy of the diagnostic approach and the interpretation of the patients' complaints. Moreover, after recovering, patients can still experience neurological symptoms. To obtain a more precise picture of the neurological manifestations and outcome of the COVID-19 infection, an international registry (ENERGY) has been created by the European Academy of Neurology in collaboration with European national neurological societies and the Neurocritical Care Society and Research Network. ENERGY can be implemented as a stand-alone instrument for patients with suspected or confirmed COVID-19 and neurological findings or as an addendum to an existing registry not targeting neurological symptoms. Data are also collected to study the impact of neurological symptoms and neurological complications on outcomes. The variables included in the registry have been selected in the interests of most countries, to favour pooling with data from other sources and to facilitate data collection even in resource-poor countries. Included are adults with suspected or confirmed COVID-19 infection, ascertained through neurological consultation, and providing informed consent. Key demographic and clinical findings are collected at registration. Patients are followed up to 12 months in search of incident neurological manifestations. As of 19 August, 254 centres from 69 countries and four continents have made requests to join the study.
COVID-19 大流行是一个全球性的公共卫生问题。多达三分之一的受影响病例报告了神经系统并发症,但它们的分布在患病率、发病率和表型特征方面存在显著差异。这种可变性主要可以通过病例的不同来源(医院与社区)、诊断方法的准确性以及对患者症状的解释来解释。此外,患者在康复后仍可能出现神经系统症状。为了更准确地了解 COVID-19 感染的神经系统表现和结果,欧洲神经病学学会与欧洲各国神经病学学会以及神经危重病学会和研究网络合作创建了一个国际登记处(ENERGY)。ENERGY 可以作为一种独立的工具用于疑似或确诊 COVID-19 且有神经系统发现的患者,也可以作为不针对神经系统症状的现有登记处的附录。还收集数据来研究神经系统症状和并发症对结局的影响。登记处中包含的变量是为了大多数国家的利益而选择的,以有利于与其他来源的数据进行汇总,并便于在资源匮乏的国家进行数据收集。包括通过神经科咨询确定的疑似或确诊 COVID-19 感染的成年人,并获得知情同意。在登记时收集关键的人口统计学和临床发现。对患者进行随访,以寻找 12 个月内的新发生的神经系统表现。截至 8 月 19 日,来自六大洲 69 个国家的 254 个中心已提出加入该研究的请求。